Online inquiry

IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1390MR)

This product GTTS-WQ1390MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL1A&IL1B gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000575.5; NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552; 3553
UniProt ID P01583; P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1390MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1144MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ6705MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ177MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ877MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ14528MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ107MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ14619MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ11927MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN2045
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW